Brief: Daiichi Sankyo - Won Approval To Market 'Vanflyta (Quizartinib)' In China For First-Line Treatment Of Flt3-Itd Mutation-Positive Acute Myeloid Leukemia
15/06/2026 09:42
BRIEF-Daiichi Sankyo - Won Approval To Market 'Vanflyta (Quizartinib)' In China For First-Line Treatment Of Flt3-Itd Mutation-Positive Acute Myeloid Leukemia June 15 (Reuters) - Daiichi Sankyo Co Ltd 4568.T:
DAIICHI SANKYO: WON APPROVAL TO MARKET 'VANFLYTA (QUIZARTINIB)' IN CHINA FOR FIRST-LINE TREATMENT OF FLT3-ITD MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA
Source text: [ID:]
Further company coverage: 4568.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Daiichi Sankyo Co
See all newsNotice Regarding Conclusion Of A Money Loan Agreement With Financial Covenants
Brief: Daiichi Sankyo - Won Approval To Market 'Vanflyta (Quizartinib)' In China For First-Line Treatment Of Flt3-Itd Mutation-Positive Acute Myeloid Leukemia
Brief: Daiichi Sankyo Concludes pCPA Letter Of Intent For Vanflyta®
Brief: AstraZeneca Says Datroway Approved In US For 1L Triple-Negative BC
Brief: EMA's CHMP Recommends Extension To Marketing Authorisation For Wegovy